Carmichael Roberts is a General Partner at North Bridge Venture Partners and the chairman of the board of 1366 Technologies Inc. Prior to joining North Bridge, Carmichael co-founded and ran several companies based predominantly on innovative materials technologies.
Prior to his entrepreneurial career, Carmichael worked in business development at GelTex Pharmaceuticals, Inc., which was acquired by Genzyme for $1.3 billion.
Prior to GelTex, Carmichael was responsible for new product and business development in the Sentry Products Specialty Materials Division of Union Carbide Corporation.
Carmichael is mainly interested in companies that make products using chemistry, materials science and/or materials engineering. He primarily focuses on very early stage ventures, including helping founders launch companies from initial formation as he did with 1366.
Carmichael received his B.S. and Ph.D. in organic chemistry from Duke University and completed his postdoctoral fellowship at Harvard University.
Carmichael also received his M.B.A. from the MIT Sloan School of Management.
Oct, 2007 - Current (about 9 years)
Founder and Chairman
Jun, 2005 - Current (over 11 years)
Board & Advisor Roles (6)Update
|Oct 26, 2015||Xconomy - Chinese Investors Looking at Boston Startups in Robotics, Biotech|
|Sep 17, 2015||Mass Device - About Us|
|Apr 7, 2015||Business Wire - CEA Chairman Adds Six Members to Board of Industry Leaders|
|Oct 31, 2014||Gigaom - Heiliger and Skok to exit North Bridge Venture Partners|
|Sep 16, 2014||Beta Boston - Morning roundup: MassChallenge startup acquired for $20 million; MC10 gets new CEO|
|Apr 4, 2014||AgFunder News - BioFuel and Ag-Product Company, Cool Planet, Raises $100M in Series D - AgFunderNews|
|Dec 5, 2012||Xconomy - Massachusetts Water Mission to Israel Looks to "Win Inbound Innovation"|
|Dec 14, 2010||Xconomy - Nano-Terra Takes in $17.2M for Nanotech Development|